We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

85 hedge funds and large institutions have $429M invested in Crinetics Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

20% more funds holding

Funds holding: 71 → 85 (+14)

0.16% more ownership

Funds ownership: 92.26% → 92.42% (+0.16%)

10% less capital invested

Capital invested by funds: $475M → $429M (-$46.5M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
85
Holders Change
+14
Holders Change %
+19.72%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
20
Increased
33
Reduced
15
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.93M
2
DCM
Driehaus Capital Management
Illinois
+$8.07M
3
BlackRock
BlackRock
New York
+$4.38M
4
BBA
Baker Bros. Advisors
New York
+$4.38M
5
Morgan Stanley
Morgan Stanley
New York
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$24.6M
2
EAM
Eventide Asset Management
Massachusetts
-$13.2M
3
OM
Opaleye Management
Massachusetts
-$3.76M
4
IC
Ikarian Capital
Texas
-$784K
5
N
Nuveen
North Carolina
-$592K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.94M -$592K -42,505 -24%
Goldman Sachs
27
Goldman Sachs
New York
$1.81M +$373K +26,790 +26%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$1.25M +$1.23M +88,644 New
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$1.14M -$72K -5,166 -6%
JP Morgan Chase
30
JP Morgan Chase
New York
$1.11M +$960K +68,921 +683%
California Public Employees Retirement System
31
California Public Employees Retirement System
California
$844K -$16.7K -1,200 -2%
AA
32
ALPS Advisors
Colorado
$839K +$244K +17,503 +42%
Two Sigma Investments
33
Two Sigma Investments
New York
$761K +$374K +26,834 +99%
Victory Capital Management
34
Victory Capital Management
Texas
$740K -$129K -9,240 -15%
Citadel Advisors
35
Citadel Advisors
Florida
$661K +$108K +7,762 +20%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$576K – – –
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$545K -$66.9K -4,800 -11%
Swiss National Bank
38
Swiss National Bank
Switzerland
$511K – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$434K +$38.7K +2,780 +10%
AllianceBernstein
40
AllianceBernstein
Tennessee
$394K +$27.9K +2,000 +8%
PP
41
PDT Partners
New York
$378K +$49.6K +3,558 +15%
Renaissance Technologies
42
Renaissance Technologies
New York
$360K +$355K +25,500 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$350K – – –
Dimensional Fund Advisors
44
Dimensional Fund Advisors
Texas
$337K +$333K +23,895 New
Wells Fargo
45
Wells Fargo
California
$327K +$46.7K +3,354 +17%
Two Sigma Advisers
46
Two Sigma Advisers
New York
$319K +$143K +10,300 +84%
VEA
47
Virtus ETF Advisers
New York
$303K +$29.5K +2,116 +11%
Deutsche Bank
48
Deutsche Bank
Germany
$289K +$70.3K +5,044 +33%
HTC
49
Hershey Trust Company
Pennsylvania
$279K – – –
Bank of America
50
Bank of America
North Carolina
$272K -$13.9K -1,000 -5%
1
2
3 4

CRNX Hedge Fund Activity: Q4 2020 in Review

85 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2020, worth a combined $429M — down 9.8% from $475M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CRNX positions and 6 closed out — a net gain of 14 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $9.93M. The largest seller was RA Capital Management, cutting an estimated $24.6M.

  • 85 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2020, up from 71 in Q3 2020.
  • Funds reported $429M of Crinetics Pharmaceuticals stock for Q4 2020, down 9.8% quarter-over-quarter.
  • 20 funds opened new Crinetics Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +14 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2020 was Point72 Asset Management, an estimated $9.93M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2020 was RA Capital Management, an estimated $24.6M sold.

Based on aggregated 13F filings for Q4 2020.